GlassScriptPhysician profile
Roy Vijay Arjoon
NPI 1407145592
$6,778.12
in general payments reported to CMS, 2019-2025
21 companies · $1,939 in 2025
The $1,939 reported for 2025 was more than what 83% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,720 · 2020: $65.91 · 2021: $74.04 · 2022: $122 · 2023: $646 · 2024: $2,211 · 2025: $1,939.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $2,811 · Food and Beverage: $1,986.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $2,810.76 |
| Food and Beverage | $1,985.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $3,850.02 | 2019-2025 | Triclip, Mitraclip |
| Edwards Lifesciences Corporation | $1,592.07 | 2024 | Evoque |
| Pfizer INC. | $168.59 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $165.31 | 2023-2024 | |
| Impulse Dynamics (USA) INC. | $157.46 | 2023-2025 | Optimizer, Optimizer |
| Amgen INC. | $157.15 | 2023-2025 | Repatha, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $117.56 | 2023-2024 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $97.29 | 2023-2024 | Wainua |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $75.76 | 2020-2024 | Lifevest |
| Ge Healthcare | $74.60 | 2025 | |
| Cvrx, INC. | $51.33 | 2024 | Barostim Neo System |
| Shockwave Medical, INC | $46.82 | 2023 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Siemens Medical Solutions USA, INC. | $43.91 | 2024 | Acuson Origin Diagnostic Ultrasound System |
| Akcea Therapeutics, INC. | $35.84 | 2020 | |
| Kiniksa Pharmaceuticals, LTD. | $35.72 | 2022-2023 | Arcalyst |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $27.91 | 2021 | |
| Abiomed | $20.64 | 2025 | |
| Medtronic, INC. | $16.18 | 2024 | Symplicity G3 |
| Kiniksa Pharmaceuticals International, Plc | $15.87 | 2024 | Arcalyst |
| Tactile Systems Technology INC | $14.42 | 2024 | Entre Plus, Flexitouch Plus |
| Lexicon Pharmaceuticals, INC. | $13.67 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roy Arjoon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.